Preclinical evaluation of safety of the new hepatoprotector maxar

A. S. Saratikov, N. S. Livshits, F. I. Burchenkova, N. G. Kadychagova, R. R. Akhmedzhanov, L. V. Bashirova

Research output: Contribution to journalArticle


The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Issue number6
Publication statusPublished - 2003

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Preclinical evaluation of safety of the new hepatoprotector maxar'. Together they form a unique fingerprint.

  • Cite this

    Saratikov, A. S., Livshits, N. S., Burchenkova, F. I., Kadychagova, N. G., Akhmedzhanov, R. R., & Bashirova, L. V. (2003). Preclinical evaluation of safety of the new hepatoprotector maxar. Eksperimental'naya i Klinicheskaya Farmakologiya, 66(6), 53-55.